Synthesis and Antineoplastic Applications of TPE Appended Organometallic Iridium(III) Complexes.

Xicheng Liu,Xiangdong He,Xiaojing Zhang,Yongling Wang,Jiaying Liu,Xiujuan Hao,Yue Zhang,Xiang-Ai Yuan,Laijin Tian,Zhe Liu
DOI: https://doi.org/10.1002/cbic.201900268
IF: 3.2
2019-01-01
ChemBioChem
Abstract:Iridium(III) complexes have attracted more and more attention in the past few years because of their potential antineoplastic activity. In this study, four Ir-III complexes of the types [(eta(5)-Cp-x)Ir(N<^>N)Cl]PF6 (complexes 1 and 2) and [Ir(Phpy)(2)(N<^>N)]PF6 (complexes 3 and 4) have been synthesized and characterized. They exhibit potential antineoplastic activity towards A549 cells, especially in the case of complex 1 [IC50=(3.56 +/- 0.5) mu m], which was nearly six times as effective as cisplatin [(21.31 +/- 1.7) mu m]. Additionally, these complexes show some selectivity towards cancer cells over normal cells. They could be transported by serum albumin (binding constants were changed from 0.37x10(5) to 81.71x10(5) m(-1)). Ir-III complexes 1 and 2 could catalyze the transformation of nicotinamide adenine dinucleotide reduced form (NADH) into NAD(+) (turnover numbers 43.2, 11.9] and induce the accumulation of reactive oxygen species, thus confirming their antineoplastic mechanism of oxidation, whereas the cyclometalated complexes 3 and 4 were able to target the lysosome [Pearson co-localization coefficient (PCC)=0.73], cause lysosomal damage, and induce apoptosis. Understanding the mechanism of action would help further structure-activity optimization on these Ir-III complexes as emerging cancer therapeutics.
What problem does this paper attempt to address?